This is a preview of subscription content, log in via an institution to check access.
Notes
The study was supported by Portola Pharmaceuticals, Inc.
Acute Medically Ill VTE Prevention with Extended Duration Betrixaban
Reference
Guy H, et al. Cost-Effectiveness of Betrixaban Compared with Enoxaparin for Venous Thromboembolism Prophylaxis in Nonsurgical Patients with Acute Medical Illness in the United States. PharmacoEconomics : 21 Dec 2018. Available from: URL: http://doi.org/10.1007/s40273-018-0757-8
Rights and permissions
About this article
Cite this article
Betrixaban for VTE prophylaxis: better outcomes, lower cost. PharmacoEcon Outcomes News 819, 10 (2019). https://doi.org/10.1007/s40274-019-5549-7
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-019-5549-7